Analysis of the characteristics of chemotherapy-resistant renal cell carcinomas based on global transcriptional analysis of their tissues and cell lines
Authors:
Takahiro Isono aff001; Masafumi Suzaki aff001
Authors place of work:
Central Research Laboratory, Shiga University of Medical Science, Otsu, Shiga, Japan
aff001
Published in the journal:
PLoS ONE 14(11)
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0225721
Summary
Starvation-resistant renal cell carcinoma (RCC) cell lines are considered dormant-state cells that survive even under glucose starvation. The cellular biological and global transcriptional analysis using these cells identified potential markers of chemotherapy-resistant RCC and therapeutic agent candidates. Recently, we showed that ARL4C was a predictive biomarker for poor prognosis in patients with chemotherapy-resistant RCC by the global transcriptional analysis of patient primary tissues. The objective of this study was to identify the characteristics of chemotherapy-resistant RCC by the global transcriptional analysis of primary tissues of patients with RCC and RCC cell lines. The connective global transcriptional analysis showed that two starvation-resistant RCC cell lines, SW839 and KMRC-1, were strongly correlated to tissues of patients with chemotherapy-resistant RCC and showed high expressions of invasive- and proliferation-related genes. We found fibronectin (FN1) expression was a predictive biomarker in some patients with chemotherapy-resistant RCC, which especially correlated with two starvation-resistant RCC cell lines. These results indicate these cell lines emulate chemotherapy-resistant RCC and might be useful in the search for markers to predict poor prognosis and in the development of therapeutic agents and their index markers for chemotherapy-resistant RCCs.
Keywords:
Cancer detection and diagnosis – biomarkers – metastasis – TGF-beta signaling cascade – Surgical resection – Prognosis – Chemotherapeutic agents – Renal cell carcinoma
Introduction
Renal cell carcinoma (RCC) is the most common renal malignancy and its incidence is currently increasing [1]. More than 30% of newly diagnosed cases are regionally-advanced or at metastatic stages. Radical nephrectomy remains the standard and only curative treatment for patients with localized RCC. However, up to half of nephrectomized patients that appear cured eventually develop distant metastases [2]. Therefore, effective anticancer drugs for metastatic RCC have been investigated, and several new molecular targeting drugs, including tyrosine kinase and mTOR inhibitors, have been developed [3–9]. However, the therapeutic efficiencies of these agents are insufficient.
Previously, we demonstrated the presence of two types of cells in RCC involved in carbon metabolism and cell signaling under glucose starvation, which is the major nutrient denied to cells following the inhibition of angiogenesis [10]. These findings suggested that differences between starvation-resistant and starvation-sensitive RCC cells might be key factors in developing novel targeted therapies. Starvation-resistant cells are dormant-state cells that survive even under glucose starvation [10]. Cell biological analysis and global transcriptional analysis using these two types of RCC cells indicated that mitochondrial manganese-dependent superoxide dismutase (SOD2) [11] and tumor necrosis factor (TNF)-related apoptosis-induced ligand (TNFSF10/TRAIL) [12] were potential markers of poor prognosis. In addition, buformin (a biguanide) [10, 11], etomoxir (an inhibitor of beta-oxidation from fatty acids) [11], and chetomin (a nuclear inhibitor of hypoxia inducible factor [HIF]) [13], may be potential therapeutic agents for RCC. Recently, we showed that seven genes searched for by the global transcriptional analysis of primary tissues from patients with RCC were useful to predict a poor prognosis in patients with chemotherapy-resistant RCC. Furthermore, ARL4C, one of these seven genes, was demonstrated to be a useful predictor of a poor prognosis in patients with chemotherapy-resistant RCC by global transcriptomic analyses. Cases with high ARL4C expression were associated with a significantly shorter survival periods than in the cases with low ARL4C expression (log-rank test, p < 0.001; 8.7 months vs not reached, respectively), and Cox univariate and multivariate analyses showed that high ARL4C expression accurately predicted poor survival in this cohort (hazard ratio = 111 and 167, p < 0.001 and p = 0.005, respectively). Moreover, these finding were independently confirmed by clinicopathological analyses of another clinical cohort [14]. However, RCC patients with high ARL4C expression are resistant to treatment with tyrosine kinase and mTOR inhibitors. Therefore, novel therapeutic agents targeting other molecules will be required for the treatment of RCC patients.
In this study, we identified the characteristics of chemotherapy-resistant RCCs by the global transcriptional analysis of primary tissues from patients with RCC and RCC cell lines. We showed that starvation-resistant cells might be useful for the development of predictive biomarkers for a poor prognosis, the development of therapeutic agents, and index markers in patients with chemotherapy-resistant RCC.
Materials and methods
Cell lines and cell culture conditions
Three starvation-resistant RCC cell lines (SW839, VMRC-RCW and KMRC-1) and four starvation-sensitive RCC cell lines (Caki1, Caki2, NC65 and ACHN) were used in this study. These cell lines were purchased from either the American Type Culture Collection, Riken Cell Bank, Cell Resource Center for Biomedical Research in Tohoku University (Sendai, Japan) or the Japanese Collection of Research Bioresources (Japan). All cell lines were maintained in RPMI 1640 (Nacalai Tesque, Kyoto, Japan), containing 25 mM glucose, supplemented with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 atmosphere.
RNA preparation
Total RNA was extracted from seven RCC cell lines using the Trizol Plus RNA Purification kit (Thermo Fisher Scientific, Waltham, MA, USA). Total RNA was quantified using a Bioanalyzer (Agilent, Santa Clara, CA, USA) according to the manufacturer’s instructions. The RNA Integrity Numbers of all prepared total RNA samples were over 8.0.
High-throughput DNA sequencing
A library of template molecules for high-throughput DNA sequencing was converted from total RNA using the TruSeq RNA Sample Prep Kitv2 (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol. The library was quantified using a Bioanalyzer (Agilent) following the manufacturer’s instructions. The library (4 pM) was subjected to cluster generation on a Single Read Flow Cell v4 (TruSeq SR Cluster Kit v2-cBot-GA) with a cBot generation instrument (Illumina). Sequencing was performed on a Genome Analyzer GAIIx for 58 cycles using Cycle Sequencing v5-GA reagents (Illumina).
Data analysis
Image analysis and base calling were performed using Real Time Analysis version 1.13 (Illumina). The sequence libraries for each sample were processed using CASAVA Software 1.8.2 (Illumina) to produce 51-bp sequence data in fastq format. The fastq files were processed using Cutadapt version 1.2.1 [15] with option–q 30. In addition, we removed reads shorter than 49-bp using Cutadapt. Trimmed reads for each sample were aligned to the reference genome (Ensembl build GRCh37) using TopHat version 2.0.10 [16] with the default setting, except for option–G. Differential gene expression analysis was performed using Cufflinks [17] with option -g. Cuffmerge was used to merge the assembled transcripts into a consensus gene track from all mapped samples with options–s and–g. Moreover, Cuffqunt was used for quantification using option–M. Cuffdiff was used to identify differentially expressed genes and transcripts between two groups containing 43 primary tissues of patients with RCC and seven RCC cell lines. Genes and transcripts were identified as being significantly differentially and are expressed with q values <0.05, calculated using the Benjamin–Hochberg FDR correction [17]. In addition, the values of fragments per kilobase of exon per million fragments mapped (FPKM) were converted from count values for the comparison of expression levels among genes. The cor_plot and prcomp package of free software R (https://www.r-project.org/) using genes.count_table following Cuffnorm were used to identify the correlation rates and the principal component analysis of 50 samples containing 43 primary tissues of patients with RCC and seven RCC cell lines, respectively. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and gene ontology (GO) analysis were performed using DAVID Bioinformatics Resources 6.8 [18]. The data of 43 primary tissues from patients with RCC were obtained from previous data deposited in the DDBJ Japanese Genotype-phenotype Archive for genetic and phenotypic human data under accession number JGAS00000000149. Data from seven RCC cell lines were deposited in the DDBJ under accession number DRA008476.
The box and whisper plot
Box and whisper plots were generated using a function of boxplot in free software R.
Receiver operating characteristic (ROC) analysis
ROC curve analysis was performed using the ROCR package in free software R and the maximum accuracy was calculated.
Statistical analysis
Data were reported as the mean ± standard error (SE). The values were derived from at least three experiments. Statistical analyses were performed using R. One-way factorial analysis of variance (ANOVA) accompanied by pair-wise comparisons using t-tests with a pooled standard deviation (SD) was used to compare the means of multiple groups. A p value < 0.05 denotes statistical significance.
Results
The correlation rates of global transcriptomic expression in primary tissues of patients with RCC and RCC cell lines
Global transcriptional analysis was performed using seven RCC cell lines and 43 primary tissues of patients with RCC using previous data deposited in the DNA Data Bank of Japan (DDBJ) Japanese Genotype-phenotype Archive for genetic and phenotypic human data under accession number JGAS00000000149. This data contained 43 primary tissues and showed the following as previously reported [14]: 27 cases in disease-free status without metastases 5 years after initial surgery for resection of the primary RCC lesion (Group q1); seven cases with survival ≥ 4 years after initial diagnosis of metastasis (Group q2); and nine cases with survival ≤ 2 years after initial diagnosis of metastasis (Group q3, chemotherapy-resistant RCCs). The correlation rates of global transcriptional expression in seven RCC cell lines to 43 tissues of RCC patients were determined by genes count values using genes.count_table of Cuffnorm. SW839 showed a > 70% correlation rate for samples number four and five in Group q3 (q3_4 and 5) and KMRC-1 also showed a > 70% correlation rate for q3_5 (Fig 1). Three tissues of Group q3 (q3_4, 5 and 6) and one tissue of Group q2 (q2_3) were significantly correlated with starvation-resistant cell lines compared with starvation-sensitive cell lines (Table 1). The starvation-resistant cell lines, SW839 and KMRC-1, were significantly correlated with Group q3 vs q1. However, VMRC-RCW, the remaining starvation-resistant cell line, did not show a correlation with the four starvation-sensitive cell lines (Table 2). These results suggested that the two starvation-resistant RCC cell lines, SW839 and KMRC-1, were strongly correlated with and indicated a poor prognosis for patients with chemotherapy-resistant RCC (Group q3), which were resistant to treatment with tyrosine kinase and mTOR inhibitors [14].
Principal component analysis of global transcriptomic expression in primary tissues of patients with RCC and RCC cell lines
Principal component analysis of global transcriptional expression with 50 samples containing 43 primary tissues of patients and seven RCC cell lines was performed (Fig 2). Four tissues, q2_3, q3_4, q3_5, and q3_6, three starvation-resistant cell lines, SW839, KMRC-1, and VMRC-RCW, and two starvation-sensitive cell lines, Caki1and Caki2, showed a positive score on Principal component 1 (contribution rate: 39.7%). Four tissues, q2_3, q3_4, q3_5, and q3_6, and KMRC-1, a starvation-resistant cell line, showed a positive score on Principal component 2 (contribution rate: 12.7%). In both Principal component 1 and 2, the highest principal component loading gene was FN1 (Table 3). These results suggested poor prognosis tissues of patients with RCC (Group q3) were separated into Subgroup q3A: q3_4, q3_5, and q3_6, whereas Subgroup q3B contained the other six samples. Furthermore, the two starvation-resistant RCC cell lines, SW839 and KMRC-1, were strongly correlated and emulated Subgroup q3A.
Global transcriptomic analysis in three chemotherapy-resistant RCC tissues and SW839 and KMRC-1 cell lines
Global transcriptional analysis was performed to profile Group A, three chemotherapy-resistant RCC tissues (Subgroup q3A) and SW839 and KMRC-1, relative to Group B containing the other 45 samples. We analyzed genes that were differentially expressed between Group A and B using Cuffdiff and identified 164 genes that were significantly up-regulated in Group A compared with Group B (S1 Table). These 164 genes were analyzed by KEGG pathway analysis and GO analysis using DAVID. KEGG pathway analysis showed that extracellular matrix (ECM)-related and cell cycle-related pathways were up-regulated in Group A (Table 4). TGFB2, ITGB1, FN1 and COL1A1 contributed to many pathways. GO analysis showed that mitosis- and cytokinesis-related genes were up-regulated in Group A (Table 5). These results suggested that three chemotherapy-resistant RCC tissues (Subgroup q3A) and two starvation-resistant RCC cell lines, SW839 and KMRC-1, showed a common malignant phenotype with invasive and proliferating activity.
Higher fibronectin (FN1) expression predicts a poor prognosis in patients with chemotherapy-resistant RCC
FN1 was the highest principal component loading gene (Table 3) and contained many up-regulated pathways in Group A (Table 4). Therefore, the present study evaluated the predictive value of FN1 for poor prognosis in 43 primary tissues from patients with RCC and seven RCC cell lines. RCC samples obtained from Group q3 (i.e., survival ≤ 2 years after initial diagnosis of metastasis) had significantly higher FN1 expression compared with samples in Group q1 surviving ≥ 5 years without metastases (Fig 3A). In addition, Subgroup q3A had significantly higher FN1 expression compared with Groups q1, q2, and Subgroup q3B (Fig 3B). Moreover, ROC curve analysis of 43 patients in this cohort (Fig 4 and Table 6) showed that FN1 predicted patient mortality caused by RCC within 2 years after the initial diagnosis of metastasis with a high maximum accuracy of 86.0% based on the cut-off FPKM value (minimum value of FPKM that showed maximum accuracy) of 3760.31. This cut-off FPKM value for poor prognosis (Group q3, survival ≤ 2 years after initial diagnosis of metastasis) separated Subgroup q3A from the other groups. Therefore, the maximum accuracy of predicting patient mortality in 16 patients with metastasis was low (0.625). However, FN1 predicted the development of metastasis in 43 patients with a high maximum accuracy of 0.814 based on the lower cut-off FPKM value of 750.53. These results showed that FN1 might be a useful predictive biomarker for poor prognosis and the development of metastasis in patients with RCC. However, FN1 might be a specific index marker of Subgroup q3A, which formed part of the poor prognosis patient group with chemotherapy-resistant RCC.
Discussion
This study showed that starvation-resistant RCC cell lines, SW839 and KMRC-1, were strongly correlated and emulated primary tissues from poor prognosis patients with chemotherapy-resistant RCC, and indicated their characteristics of chemotherapy-resistant RCC, which was useful for the search of markers to predict poor prognosis and the development of therapeutic agents and their index markers for chemotherapy-resistant RCCs.
The global transcriptional analysis of 43 primary tissues from patients with RCC and seven RCC cell lines showed that starvation-resistant RCC cell lines, SW839 and KMRC-1, were strongly correlated to primary tissues of poor prognosis patients with chemotherapy-resistant RCC, especially three of nine primary tissues from RCC patients. Their cell lines and tissues formed a group (Group A) that had a common malignant phenotype of maintaining invasive and proliferating activities compared with other cell lines and tissues as determined by their gene expression pattern. We previously reported that starvation-sensitive RCC cell lines showed G2/M-phase arrest under glucose deprivation leading to cell death, but that starvation-resistant RCC cell lines containing SW839 and KMRC-1 survived under glucose deprivation without the induction of G2/M transition-arrest [10]. This report is consistent with the result that mitosis-related genes were up-regulated in Group A. Therefore, chemotherapy-resistant RCCs may escape cell death induced by G2/M transition-arrest in the tumor microenvironment where nutrients such as glucose are deficient. Another previous study reporting that KMRC-1was highly invasive [14] was also consistent with the result whereby ECM-related genes were up-regulated in Group A. These results suggest that the characteristics of SW839 and KMRC-1 strongly emulated chemotherapy-resistant RCCs.
SW839, KMRC-1, and primary tissues from poor prognosis patients with chemotherapy-resistant RCC up-regulated expression of FN1, an ECM-related gene, compared with other cell lines and tissues. Therefore, this study indicates that FN1 expression might be a useful marker to predict a poor prognosis as previously reported [19]. However, our results showed that FN1 expression was a predictive biomarker of a group of poor prognosis patients with chemotherapy-resistant RCC, termed Subgroup q3A. Makers for specific subgroup of patients will be useful in combination with markers used to cover total patients. For patients with RCC, FN1 expression will be useful in combination with a predictive biomarker of poor prognosis such as ARL4C, which predicts patient mortality caused by RCC within 2 years after the initial diagnosis of metastasis with a high accuracy of 97.7% [14]. SW839 and KMRC-1 were useful in the search for a marker to predict a poor prognosis in patients with RCC. Some genes specifically up-regulated in SW839 and KMRC-1 were also candidates for poor prognosis markers in chemotherapy-resistant RCCs.
Starvation-resistant RCC cell lines, including VMRC-RCW as well as SW839 and KMRC-1, were previously reported to undergo cell death induced by buformin (a biguanide) [10, 11], etomoxir (an inhibitor of beta-oxidation from fatty acids) [11], and chetomin (a nuclear inhibitor of hypoxia inducible factor [HIF]) [13]. These drugs may be potential therapeutic agents for malignant RCCs. Therefore, drug screening using starvation-resistant RCC cell lines will be useful for the development of therapeutic agents for malignant RCCs. Of note, drug repositioning (e.g. biguanide) using SW839 and KMRC-1 may be effective.
In the last few decades, the treatment for advanced RCC has evolved dramatically due to the introduction of targeted therapies and novel immunotherapies using checkpoint inhibitors. The CheckMate-214 trial showed the survival superiority of combined immunotherapy over targeted therapy in a cohort of patients at intermediate or poor-risk [20]. CD274 (PDL1), a target of checkpoint inhibitors, was an up-regulated gene in Group A compared with Group B (S1 Table). Therefore, SW839 and KMRC-1 may be effective for the search of checkpoint inhibitors.
It is important to identify index markers for the clinical application of potential therapeutic agents. The connection of data from global transcriptional analysis of clinical RCC tissues and RCC cell lines will identify candidate index markers of therapeutic agents, which can be screened using the KMRC-1 and SW839 cell lines.
Conclusions
This study showed that starvation-resistant RCC cell lines, SW839 and KMRC-1, emulated chemotherapy-resistant RCC and therefore will be useful for identifying markers to predict poor prognosis and the development of therapeutic agents and their index markers for chemotherapy-resistant RCCs.
Supporting information
S1 Table [docx]
List of genes that were significantly up-regulated in Group A compared with Group B.
Zdroje
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30. doi: 10.3322/caac.21442 29313949
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–386. doi: 10.1002/ijc.29210 25220842
3. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma 2014 update. Eur Urol. 2015; 67: 913–924. doi: 10.1016/j.eururo.2015.01.005 25616710
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125–134. doi: 10.1056/NEJMoa060655 17215530
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007; 356: 115–124. doi: 10.1056/NEJMoa065044 17215529
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103–2111. doi: 10.1016/S0140-6736(07)61904-7 18156031
7. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007; 8: 975–984. doi: 10.1016/S1470-2045(07)70285-1 17959415
8. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010; 28: 475–480. doi: 10.1200/JCO.2008.21.6994 20008644
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271–2281. doi: 10.1056/NEJMoa066838 17538086
10. Isono T, Chano T, Kitamura A, Yuasa T. Glucose deprivation induces G2/M transition-arrest and cell death in N-GlcNAc2-modified protein-producing renal carcinoma cells. PLoS One. 2014; 9: e96168. doi: 10.1371/journal.pone.0096168 24796485
11. Isono T, Chano T, Yonese J, Yuasa T. Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas. Sci Rep. 2016; 6: e25669. doi: 10.1038/srep25669 27157976
12. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Yonese J, et al. Abundance of TRAIL attenuated by HIF2α and c-FLIP affects prognosis in malignant renal cell carcinomas. Oncotarget. 2018; 9: 23091–23101. doi: 10.18632/oncotarget.25214 29796174
13. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Suzaki M, et al. Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas. Am J Cancer Res. 2016; 6: 2263–2276. 27822416
14. Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, et al. ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma. Am J Cancer Res. 2019; 9: 415–423. 30906638
15. Martin M. Cutadapt removes adapter sequences from high through put sequencing reads. EMB Net J. 2011;17: 10–12.
16. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14: R36. doi: 10.1186/gb-2013-14-4-r36 23618408
17. Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotech. 2010; 28: 511–515. doi: 10.1038/nbt.1621 20436464
18. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protoc. 2009; 4: 44–57. doi: 10.1038/nprot.2008.211 19131956
19. Steffens S, Schrader AJ, Vetter G, Eggers H, Blasig H, Becker J, et al. Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol. Lett. 2012; 3: 787–790. doi: 10.3892/ol.2012.566 22740994
20. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378: 1277–1290. doi: 10.1056/NEJMoa1712126 29562145
Článek vyšel v časopise
PLOS One
2019 Číslo 11
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Je libo čepici místo mozkového implantátu?
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
- AI může chirurgům poskytnout cenná data i zpětnou vazbu v reálném čase
- Nová metoda odlišení nádorové tkáně může zpřesnit resekci glioblastomů
Nejčtenější v tomto čísle
- A daily diary study on maladaptive daydreaming, mind wandering, and sleep disturbances: Examining within-person and between-persons relations
- A 3’ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction
- A substitution mutation in a conserved domain of mammalian acetate-dependent acetyl CoA synthetase 2 results in destabilized protein and impaired HIF-2 signaling
- Molecular validation of clinical Pantoea isolates identified by MALDI-TOF
